Sikkim Journal

(Albany, US), October 28, 2026 – DelveInsight’s ‘Chondrosarcoma Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of chondrosarcoma, historical and forecasted epidemiology, as well as the chondrosarcoma market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Explore the intricate details of the Chondrosarcoma Market Report @ Chondrosarcoma Market Size

Key Takeaways from the Chondrosarcoma Market Report

• In June 2026, Inhibrx Biosciences, Inc. announced that the U.S. FDA had accepted for filing its Biologics License Application (BLA) for ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA reported no filing review issues at that time and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 14, 2027.

• According to DelveInsight’s analysis, the chondrosarcoma market size was found to be ~USD 15 million in the 7MM in 2025, and it is projected to grow at a CAGR of 16% during 2026–2036.

• Among the 7MM, the US chondrosarcoma market accounted for the largest market size, at ~USD 10 million in 2025.

• According to DelveInsight’s estimates, the total incident cases of chondrosarcoma in the 7MM were approximately 2,300 in 2025.

• Conventional chondrosarcomas constitute approximately 80% of all chondrosarcoma cases, making them the most prevalent subtype.

• IDH mutations are found in 50-70% of chondrosarcomas, and nearly 65% of cases are related to IDH mutations, leaving a wide opportunity for targeted therapies in the untapped chondrosarcoma market.

• There are no approved therapies for chondrosarcoma, and surgery remains the mainstay of treatment.

• The leading chondrosarcoma companies include Servier, Inhibrx, and others.

• Promising chondrosarcoma therapies include ivosidenib, INBRX-109 (ozekibart), and others.

Get a Free sample for the Chondrosarcoma Market Forecast, Size & Share Analysis Report @ Chondrosarcoma Market Share

Chondrosarcoma Overview

Chondrosarcoma comprises a group of locally aggressive or malignant cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior. A type of bone cancer, it is categorized into four grades (I, II, III, and IV), with the majority of cases falling within Grade II. Chondrosarcoma primarily affects adults and is the second most common primary solid tumor of bone after osteogenic sarcoma, which also shapes the wider osteosarcoma market and bone cancer treatment market. It is classified as primary or secondary depending on whether the tumor arises de novo or develops in a preexisting benign cartilage neoplasm. It predominantly affects individuals in the fourth to sixth decades of life, and the most commonly involved sites are the pelvic bones, followed by the femur, humerus, and ribs.

Diagnosis begins with a review of the patient’s medical history and a physical examination. Imaging tests such as X-rays, CT scans, and MRI scans are then used to assess the tumor’s size, location, and extent. A biopsy is performed for microscopic examination by a pathologist to confirm the diagnosis. The tumor tissue is graded from I to IV to determine its aggressiveness and prognosis, and staging tests may follow to assess the cancer’s spread.

Download the report to understand which factors are driving Chondrosarcoma Epidemiology trends @ Chondrosarcoma Market Analysis

Chondrosarcoma Epidemiology Segmentation in the 7MM

• Total Incident Cases of Chondrosarcoma

• Primary Incident Cases of Chondrosarcoma

• Grade-specific Incident Cases of Chondrosarcoma

• Mutation-specific Incident Cases of Chondrosarcoma

• Stage-specific Incident Cases of Chondrosarcoma

Chondrosarcoma Epidemiology Key Findings

• In 2025, the total number of incident cases of chondrosarcoma in the 7MM was ~2,300.

• Among the stage-specific incident cases of chondrosarcoma, localized cases contribute the most in Japan.

• Conventional chondrosarcomas constitute approximately 80% of all chondrosarcoma cases, making them the most prevalent subtype.

• IDH mutations are detected in approximately 50% of chondrosarcoma patients in Japan.

Approved Therapies for Chondrosarcoma

Currently, there is no approved drug for the treatment of chondrosarcoma. As per the updated NCCN guidelines, ivosidenib has been added as a treatment option for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma; however, for all types of chondrosarcoma, the premise for curative treatment is adequate surgery.

Chondrosarcoma Pipeline Analysis

• Ivosidenib: Servier

Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor developed by Servier. A Phase III, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib is underway for participants aged 18 years and older with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation, whether untreated or previously treated with one systemic treatment regimen, a key development for the metastatic conventional chondrosarcoma market. These mutations lead to abnormal forms of IDH1 proteins in the cancer cells.

• INBRX-109 (Ozekibart): Inhibrx

INBRX-109 is the most advanced therapeutic candidate of Inhibrx and is designed to target tumor-biased direct cell death induction by DR5 activation in numerous cancer types. It is a tetravalent DR5 agonistic antibody that can potentiate DR5 through efficient receptor clustering, causing cell death. Inhibrx plans to file a BLA in Q2 of 2026, and the drug is currently being evaluated in a potentially registration-enabling Phase II trial.

Discover more about therapies set to grab Major Chondrosarcoma Market Share @ Chondrosarcoma Market Trends

Chondrosarcoma Market Outlook

The current management of chondrosarcoma depends on the type, the grade, and the location of the tumor, while the best predictor of clinical behavior is the grading system. Surgical treatment is considered the best and only treatment for chondrosarcoma, as radiotherapy and chemotherapy are rendered unresponsive and refractory. Curettage, radical resection, and amputation are the primary surgical options, based on factors such as the size and site of the lesion and its degree of malignancy.

A major roadblock in estimating the revenue generated by systemic agents in the bone cancer drug market for chondrosarcoma is that chemotherapy is generally ineffective in conventional chondrosarcoma, and there is no standard systemic therapy for advanced conventional chondrosarcoma. The rarity of these cancers also makes randomized clinical trials more challenging. Current chemotherapy recommendations include cisplatin and doxorubicin, extrapolated from regimens for osteosarcoma and Ewing sarcoma. Other combinations of gemcitabine, ifosfamide, dasatinib, and pazopanib have also been used, but with limited success, especially in dedifferentiated and metastatic cases.

The US accounted for the largest share of the chondrosarcoma market in the 7MM, at ~USD 10 million in 2025. The entry of mid-stage candidates such as INBRX-109 (ozekibart) is expected to intensify competition in the chondrosarcoma treatment landscape during the latter half of the forecast period.

Key Factors Driving the Chondrosarcoma Market

• Rising Disease Incidence: Increased detection rates due to advanced imaging and better diagnostic sensitivity are leading to higher reported cases, enhancing the treated patient population.

• Emergence of Targeted Therapies: Research into targeted agents, including IDH1/2 inhibitors (ivosidenib), EZH2 inhibitors, and DR5-targeted agents like INBRX-109, is transforming treatment for unresectable cases.

Chondrosarcoma Market Drivers

• Rising demand for targeted and personalized therapies.

• Increasing awareness and early diagnosis of chondrosarcoma.

• Advancements in molecular diagnostics and genetic profiling.

• Growing investment in oncology research and drug development.

• Limited treatment options driving demand for novel therapies.

Chondrosarcoma Market Barriers

• Limited treatment options for advanced chondrosarcoma.

• Resistance to conventional chemotherapy and radiotherapy.

• Challenges in early diagnosis and accurate tumor classification.

• High costs of surgery and specialized treatments.

• Limited clinical trials and targeted therapy development.

Chondrosarcoma Treatment Landscape

The grade of malignancy and the underlying subentity strongly determine the therapy and prognosis of chondrosarcoma. For all types, the premise for curative treatment is adequate surgery, and only wide compartmental tumor resection, according to Enneking, can control the tumor locally and systemically in a curative setting in high and intermediate-grade tumors. Neoadjuvant or adjuvant chemotherapy may provide a survival advantage in dedifferentiated chondrosarcoma, and the regimen is often based on a combination of doxorubicin and cisplatin or ifosfamide. Local recurrence and metastatic progression are common in aggressive subtypes, with poor long-term survival rates in metastatic disease.

To know more about Chondrosarcoma Companies working in the treatment market, visit @ Chondrosarcoma Market Insights

Scope of the Chondrosarcoma Market Report

• Coverage: 7MM

• Study Period: 2022–2036

• Forecast Period: 2026–2036

• Chondrosarcoma Companies: Servier, Inhibrx, and others

• Chondrosarcoma Therapies: Ivosidenib, INBRX-109 (ozekibart), and others

• Chondrosarcoma Market Dynamics: Addressable patient population, market drivers and market barriers

• Chondrosarcoma Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis

• Chondrosarcoma Unmet Needs, KOL Views, Cost Assumptions and Pricing Analogues, Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Methodology of Chondrosarcoma

6. Chondrosarcoma Market Overview at a Glance

7. Disease Background and Overview of Chondrosarcoma

8. Epidemiology and Patient Population of Chondrosarcoma

9. Patient Journey of Chondrosarcoma

10. Emerging Therapies

11. Chondrosarcoma: Seven Major Market Analysis

12. Unmet Needs of Chondrosarcoma

13. SWOT Analysis of Chondrosarcoma

14. KOL Views of Chondrosarcoma

15. Market Access and Reimbursement of Chondrosarcoma

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chondrosarcoma-market